Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sphingolipids in Alzheimer's disease, how can we target them?
Crivelli SM, Giovagnoni C, Visseren L, Scheithauer AL, de Wit N, den Hoedt S, Losen M, Mulder MT, Walter J, de Vries HE, Bieberich E, Martinez-Martinez P. Crivelli SM, et al. Among authors: giovagnoni c. Adv Drug Deliv Rev. 2020;159:214-231. doi: 10.1016/j.addr.2019.12.003. Epub 2020 Jan 3. Adv Drug Deliv Rev. 2020. PMID: 31911096 Review.
Ceramide analog [18F]F-HPA-12 detects sphingolipid disbalance in the brain of Alzheimer's disease transgenic mice by functioning as a metabolic probe.
Crivelli SM, van Kruining D, Luo Q, Stevens JAA, Giovagnoni C, Paulus A, Bauwens M, Berkes D, de Vries HE, Mulder MT, Walter J, Waelkens E, Derua R, Swinnen JV, Dehairs J, Mottaghy FM, Losen M, Bieberich E, Martinez-Martinez P. Crivelli SM, et al. Among authors: giovagnoni c. Sci Rep. 2020 Nov 9;10(1):19354. doi: 10.1038/s41598-020-76335-4. Sci Rep. 2020. PMID: 33168861 Free PMC article.
CERTL reduces C16 ceramide, amyloid-β levels, and inflammation in a model of Alzheimer's disease.
Crivelli SM, Luo Q, Stevens JAA, Giovagnoni C, van Kruining D, Bode G, den Hoedt S, Hobo B, Scheithauer AL, Walter J, Mulder MT, Exley C, Mold M, Mielke MM, De Vries HE, Wouters K, van den Hove DLA, Berkes D, Ledesma MD, Verhaagen J, Losen M, Bieberich E, Martinez-Martinez P. Crivelli SM, et al. Among authors: giovagnoni c. Alzheimers Res Ther. 2021 Feb 17;13(1):45. doi: 10.1186/s13195-021-00780-0. Alzheimers Res Ther. 2021. PMID: 33597019 Free PMC article.
FTY720 decreases ceramides levels in the brain and prevents memory impairments in a mouse model of familial Alzheimer's disease expressing APOE4.
Crivelli SM, Luo Q, Kruining DV, Giovagnoni C, Mané-Damas M, den Hoedt S, Berkes D, De Vries HE, Mulder MT, Walter J, Waelkens E, Derua R, Swinnen JV, Dehairs J, Wijnands EPM, Bieberich E, Losen M, Martinez-Martinez P. Crivelli SM, et al. Among authors: giovagnoni c. Biomed Pharmacother. 2022 Aug;152:113240. doi: 10.1016/j.biopha.2022.113240. Epub 2022 Jun 9. Biomed Pharmacother. 2022. PMID: 35689862 Free article.
Altered sphingolipid function in Alzheimer's disease; a gene regulatory network approach.
Giovagnoni C, Ali M, Eijssen LMT, Maes R, Choe K, Mulder M, Kleinjans J, Del Sol A, Glaab E, Mastroeni D, Delvaux E, Coleman P, Losen M, Pishva E, Martinez-Martinez P, van den Hove DLA. Giovagnoni C, et al. Neurobiol Aging. 2021 Jun;102:178-187. doi: 10.1016/j.neurobiolaging.2021.02.001. Epub 2021 Feb 7. Neurobiol Aging. 2021. PMID: 33773368 Free article.
The Effect of FTY720 on Sphingolipid Imbalance and Cognitive Decline in Aged EFAD Mice.
Luo Q, Crivelli SM, Zong S, Giovagnoni C, van Kruining D, Mané-Damas M, den Hoedt S, Berkes D, De Vries HE, Mulder MT, Walter J, Waelkens E, Derua R, Swinnen JV, Dehairs J, Losen M, Martinez-Martinez P. Luo Q, et al. Among authors: giovagnoni c. J Alzheimers Dis Rep. 2024 Sep 27;8(1):1317-1327. doi: 10.3233/ADR-230053. eCollection 2024. J Alzheimers Dis Rep. 2024. PMID: 39434823 Free PMC article.